Novel GPCR paradigms at the μ-opioid receptor

Georgina Louise Thompson, Eamon Kelly, Arthur Christopoulos, Meritxell Canals

Research output: Contribution to journalArticleResearchpeer-review

34 Citations (Scopus)

Abstract

Opioids, such as morphine, are the most clinically useful class of analgesic drugs for the treatment of acute and chronic pain. However, the use of opioids is greatly limited by the development of severe adverse side effects. Consequently, drug discovery efforts have been directed towards improving the therapeutic profile of opioid-based treatments. Opioid receptors are members of the family of GPCRs. As such, the recent GPCR paradigms of biased agonism and allosterism may provide novel avenues for more effective analgesics. Biased agonism (or functional selectivity) has been described for all the opioid receptor family members. Furthermore, the first allosteric modulators of opioid receptors have very recently been described. However, identification and quantification of biased agonism in a manner that is informative to medicinal chemists and drug discovery programmes still remains a challenge. In this review, we examine the progress, to date, towards identification and quantification of biased agonism and allosterism at the μ-opioid receptor in the context of its implications for the discovery of better and safer analgesics.
Original languageEnglish
Pages (from-to)287-296
Number of pages10
JournalBritish Journal of Pharmacology
Volume172
Issue number2
DOIs
Publication statusPublished - 2015

Keywords

  • allosterism
  • biased-agonism
  • GPCR
  • μ-opioid receptor

Cite this

Thompson, Georgina Louise ; Kelly, Eamon ; Christopoulos, Arthur ; Canals, Meritxell. / Novel GPCR paradigms at the μ-opioid receptor. In: British Journal of Pharmacology. 2015 ; Vol. 172, No. 2. pp. 287-296.
@article{fb15d3eb2a9546e9b285f835f7bb9496,
title = "Novel GPCR paradigms at the μ-opioid receptor",
abstract = "Opioids, such as morphine, are the most clinically useful class of analgesic drugs for the treatment of acute and chronic pain. However, the use of opioids is greatly limited by the development of severe adverse side effects. Consequently, drug discovery efforts have been directed towards improving the therapeutic profile of opioid-based treatments. Opioid receptors are members of the family of GPCRs. As such, the recent GPCR paradigms of biased agonism and allosterism may provide novel avenues for more effective analgesics. Biased agonism (or functional selectivity) has been described for all the opioid receptor family members. Furthermore, the first allosteric modulators of opioid receptors have very recently been described. However, identification and quantification of biased agonism in a manner that is informative to medicinal chemists and drug discovery programmes still remains a challenge. In this review, we examine the progress, to date, towards identification and quantification of biased agonism and allosterism at the μ-opioid receptor in the context of its implications for the discovery of better and safer analgesics.",
keywords = "allosterism, biased-agonism, GPCR, μ-opioid receptor",
author = "Thompson, {Georgina Louise} and Eamon Kelly and Arthur Christopoulos and Meritxell Canals",
year = "2015",
doi = "10.1111/bph.12600",
language = "English",
volume = "172",
pages = "287--296",
journal = "British Journal of Pharmacology",
issn = "1476-5381",
publisher = "Wiley-Blackwell",
number = "2",

}

Novel GPCR paradigms at the μ-opioid receptor. / Thompson, Georgina Louise; Kelly, Eamon; Christopoulos, Arthur; Canals, Meritxell.

In: British Journal of Pharmacology, Vol. 172, No. 2, 2015, p. 287-296.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Novel GPCR paradigms at the μ-opioid receptor

AU - Thompson, Georgina Louise

AU - Kelly, Eamon

AU - Christopoulos, Arthur

AU - Canals, Meritxell

PY - 2015

Y1 - 2015

N2 - Opioids, such as morphine, are the most clinically useful class of analgesic drugs for the treatment of acute and chronic pain. However, the use of opioids is greatly limited by the development of severe adverse side effects. Consequently, drug discovery efforts have been directed towards improving the therapeutic profile of opioid-based treatments. Opioid receptors are members of the family of GPCRs. As such, the recent GPCR paradigms of biased agonism and allosterism may provide novel avenues for more effective analgesics. Biased agonism (or functional selectivity) has been described for all the opioid receptor family members. Furthermore, the first allosteric modulators of opioid receptors have very recently been described. However, identification and quantification of biased agonism in a manner that is informative to medicinal chemists and drug discovery programmes still remains a challenge. In this review, we examine the progress, to date, towards identification and quantification of biased agonism and allosterism at the μ-opioid receptor in the context of its implications for the discovery of better and safer analgesics.

AB - Opioids, such as morphine, are the most clinically useful class of analgesic drugs for the treatment of acute and chronic pain. However, the use of opioids is greatly limited by the development of severe adverse side effects. Consequently, drug discovery efforts have been directed towards improving the therapeutic profile of opioid-based treatments. Opioid receptors are members of the family of GPCRs. As such, the recent GPCR paradigms of biased agonism and allosterism may provide novel avenues for more effective analgesics. Biased agonism (or functional selectivity) has been described for all the opioid receptor family members. Furthermore, the first allosteric modulators of opioid receptors have very recently been described. However, identification and quantification of biased agonism in a manner that is informative to medicinal chemists and drug discovery programmes still remains a challenge. In this review, we examine the progress, to date, towards identification and quantification of biased agonism and allosterism at the μ-opioid receptor in the context of its implications for the discovery of better and safer analgesics.

KW - allosterism

KW - biased-agonism

KW - GPCR

KW - μ-opioid receptor

UR - http://onlinelibrary.wiley.com.ezproxy.lib.monash.edu.au/doi/10.1111/bph.12600/epdf

U2 - 10.1111/bph.12600

DO - 10.1111/bph.12600

M3 - Article

VL - 172

SP - 287

EP - 296

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 1476-5381

IS - 2

ER -